Jefferies analyst Kelly Shi initiated coverage of Verastem (VSTM) with a Buy rating and $15 price target The company has an FDA action date on June 30 for low-grade serous ovarian cancer, a rare ovarian cancer with no approved therapies, the analyst tells investors in a research note. The firm’s key opinion leader feedback suggests “strong adoption enthusiasm” not only in the potential on-label KRASm population but also the rest due to the clinical profile and unmet need.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem price target lowered to $8 from $9 at Mizuho
- Verastem Oncology Reports Progress in Cancer Treatments
- Verastem price target raised to $14 from $13 at Guggenheim
- Verastem’s Promising Financial Outlook and Strategic Advancements Drive Buy Rating
- Verastem price target raised to $10 from $7 at H.C. Wainwright